Potassium bicarbonate 500mg capsules

BackgroundPatients with chronic kidney disease (CKD) often experience a decline in muscle mass and metabolic disturbances, which may increase the risk of cardiovascular events and all-cause mortality. Sodium bicarbonate, cholecalciferol, and protein supplementation are commonly used pharmacological and nutritional interventions; however, systematic evidence comparing their effects on muscle mass, metabolic status, and related outcomes in CKD patients remains lacking.MethodsWe systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from inception to July 1, 2025, and included eligible comparative clinical studies. Conventional meta-analysis and network meta-analysis (NMA) were used to compare the three categories of interventions in outcomes such as muscle mass, muscle function, and serum metabolic parameters, and surface under the cumulative ranking curve (SUCRA) values were used to rank intervention effects.ResultsA total of 22 studies involving 2,879 patients were included, comprising 11 on sodium bicarbonate, 5 on cholecalciferol, and 6 on protein supplementation. Conventional meta-analysis indicated that sodium bicarbonate may be more effective in improving HCO₃- and potassium levels in the early stage and may have certain effects on eGFR and systolic blood pressure at 24 months. NMA results showed that cholecalciferol was advantageous in increasing muscle mass (SMD = 0.68, 95% CI = 0.09 to 1.27), sodium bicarbonate performed better in improving serum albumin (SMD = 0.50, 95% CI = 0.01 to 0.99), and protein supplementation ranked highest for reducing serum phosphorus (SUCRA = 64.9%) and the incidence of adverse events (SUCRA = 71.9%). However, no significant differences were observed among the three interventions in muscle mass or serum metabolic parameters.ConclusionSodium bicarbonate and cholecalciferol may have potential advantages in improving serum albumin and increasing muscle mass, respectively. While protein supplementation may offer some value in reducing serum phosphorus and the incidence of adverse events. Given the limited number of included studies, small sample sizes, and substantial heterogeneity in intervention protocols, these conclusions should be further validated in future large-scale, rigorously designed randomized controlled trials.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251126837, identifier PROSPERO (CRD420251126837).

Abstract licence: CC BY

BackgroundDiabetic ketoacidosis (DKA) is a severe diabetes complication managed with fluids, insulin and electrolyte correction. This review evaluates the debated effectiveness of bicarbonate therapy on DKA outcomes.MethodsFollowing PRISMA guidelines, we systematically reviewed studies on bicarbonate therapy in DKA. We searched PubMed, Google Scholar, the Cochrane Library and ClinicalTrials.gov (as of August 2024), including studies on patients with DKA. Meta-analysis was conducted using RevMan. Bias risk was assessed with the Newcastle-Ottawa Scale (NOS) for cohort studies, Cochrane's ROB-2 for RCTs and the Joanna Briggs Institute (JBI) Scale for case series. Prospero ID: CRD42024581810.ResultsEight studies, including 646 patients, met the inclusion criteria. Participants' mean ages spanned from approximately 9.7 years to 45.8 years. Bicarbonate therapy did not significantly improve pH levels (mean difference = -0.02, 95% CI [-0.13, 0.09], p = 0.7), time to resolution of acidosis (mean difference = 0.09 h, 95% CI [-2.6, 2.79], p = 0.95) or potassium levels (mean difference = -0.10, 95% CI [-0.49, 0.29], p = 0.61). Bicarbonate therapy was associated with a marginally longer duration of hospital stay (mean difference = 13.63 h, 95% CI [0.23, 27.03], p = 0.05), although the overall effect size was small. No significant difference was observed in the incidence of hypoglycemia (odds ratio = 2.62, 95% CI [0.59, 11.63], p = 0.20). High heterogeneity was observed across most outcomes, mainly due to variability in study protocols and patient populations.ConclusionBicarbonate therapy provided no meaningful clinical benefit in the routine management of DKA and was associated with potential harm, including worsened hyperglycemia. Consistent with current guidelines, its use should be restricted to cases of severe acidemia (pH < 6.9). Further high-quality studies are needed to clarify its role in extreme acidosis and to explore alternative buffering strategies.

Abstract licence: CC BY

Distal renal tubular acidosis (dRTA) is a rare disorder characterized by normal anion gap metabolic acidosis and hypokalaemia. Physiological changes during pregnancy may aggravate acid-base imbalance and influence foetal outcomes. A 40-year-old pregnant woman at 24-25 weeks of gestation presented with recurrent hypokalaemia and lower limb weakness. Laboratory findings showed normal anion gap metabolic acidosis, consistent with dRTA. The patient was treated with oral potassium supplementation and intravenous sodium bicarbonate, resulting in clinical improvement. In the third trimester, intrauterine growth restriction was identified. Delivery at term resulted in a live neonate with low birth weight.A literature review was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines using PubMed, ScienceDirect, Wiley Online Library, SpringerLink, and ResearchGate for studies published between 2016 and 2026. Ten case reports met the inclusion criteria. Distal RTA was the most frequently reported subtype, accounting for 80% of cases. Most cases (70%) were first diagnosed during pregnancy. The most common treatment strategy was potassium supplementation combined with bicarbonate therapy (90%), administered either orally, intravenously, or as combination therapy. Adverse neonatal outcomes were reported in 50% of cases. Distal RTA should be considered in pregnant patients presenting with recurrent hypokalaemia and muscle weakness. Early recognition and appropriate correction of electrolyte imbalance and metabolic acidosis are essential to optimize maternal and foetal condition. Further studies are needed to better define clinical characteristics and management strategies of renal tubular acidosis during pregnancy. Vigilance is essential for rare distal renal tubular acidosis (dRTA)-pregnancy overlap As the leading form of RTA, (seen in 80% of reported cases), distal RTA (dRTA) frequently first appears during pregnancy (70% of instances), where it closely resembles routine hypokalaemic conditions. Clinicians should routinely check for anion-gap metabolic acidosis in pregnant women experiencing repeated muscle weakness, allowing timely treatment to avert severe maternal decline.Bicarbonate and potassium therapy boosts maternal-foetal success In this case, combined oral and intravenous replacement (effective in 90% of documented scenarios) quickly alleviated symptoms, yet the 50% chance of neonatal issues like intrauterine growth restriction or low birth weight underscores the approach's value for the foetus, providing internists with a reliable, safe strategy amid pregnancy's natural acid-base changes.Diagnostic pathway to reveal hidden dRTA dangers This experience arms internists with a straightforward algorithm (start with hypokalaemia evaluation, advance to acidosis testing) that cuts late-pregnancy risks, especially in settings with limited resources.

Abstract licence: CC BY-NC-ND